Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2019 | Enhancer landscape in CLL upon BTK inhibition

Efterpi Kostareli • 2 Apr 2019
BSH 2019
Chronic Lymphocytic Leukemia Leukemia Ibrutinib

Efterpi Kostareli, PhD, Queen’s University Belfast, Belfast, UK, speaks at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK. She discusses the enhancer landscape in chronic lymphocytic leukemia (CLL) upon BTK inhibition. Using pre and post ibrutinib treatment CLL patient samples, a longitudinal analysis of global post-translational modifications (PTMs) revealed significant heterogeneity between patients and time points.

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals